CVT-E002 stimulates the immune system and extends the life span of mice bearing a tumor of viral origin.

This study represents the first in vivo demonstration of the anticancer efficacy of CVT-E002 in an animal model. CVT-E002 treatment significantly elevated the absolute numbers of natural killer cells and monocytes and reduced the number of tumor cells in the bone marrow and spleen. This study has shown that (1) approximately 30 to 50% of tumor-bearing mice administered CVT-E002 at a dose of 40 mg/d achieved a significantly extended life span, and (2) dosage is critical in producing these ameliorative effects. PMID: 19883528 [PubMed - indexed for MEDLINE]
Source: Journal of the Society for Integrative Oncology - Category: Cancer & Oncology Tags: J Soc Integr Oncol Source Type: research